{
    "paper_id": "bbc1fb9a060a2438e55531761496cbd2f390ac55",
    "metadata": {
        "title": "Deep sequencing of B cell",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Deep sequencing of B cell receptor (BCR) heavy chains from a cohort of 19 COVID-19 27 patients from the UK reveals a stereotypical naive immune response to SARS-CoV-2 which is 28 consistent across patients and may be a positive indicator of disease outcome. Clonal 29 expansion of the B cell memory response is also observed and may be the result of memory 30 bystander effects. There was a strong convergent sequence signature across patients, and 31",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "we identified 777 clonotypes convergent between at least four of the COVID-19 patients, 32",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "but not present in healthy controls. A subset of the convergent clonotypes were 33 homologous to known SARS and SARS-CoV-2 spike protein neutralising antibodies. 34",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Convergence was also demonstrated across wide geographies by comparison of data sets 35 between patients from UK, USA and China, further validating the disease association and 36",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "consistency of the stereotypical immune response even at the sequence level. These 37 convergent clonotypes provide a resource to identify potential therapeutic and prophylactic 38",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "antibodies and demonstrate the potential of BCR profiling as a tool to help understand and 39",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "predict positive patient responses. Since the report of the first patients in December 2019 1,2 , the unprecedented global scale of 47 the COVID-19 pandemic has become apparent. The infectious agent, the SARS-CoV-2 48 betacoronavirus 3 , causes mild symptoms in most cases but can cause severe respiratory 49 diseases such as acute respiratory distress syndrome in some individuals. Risk factors for 50",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "severe disease include age, male gender and underlying co-morbidities 4 . 51",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Understanding the immune response to SARS-CoV-2 infection is critical to support 52 the development of therapies. Recombinant monoclonal antibodies derived from analysis of 53 B cell receptor (BCR) repertoires in infected patients or the immunisation of animals have 54 been shown to be effective against several infectious diseases including Ebola virus 5 , rabies 55 6 and respiratory syncytial virus disease 7 . Such therapeutic antibodies have the potential to 56",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "protect susceptible populations as well as to treat severe established infections. 57",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "While many vaccine approaches are underway in response to the SARS-CoV-2 58 outbreak, many of these compositions include as immunogens either whole, attenuated 59 virus or whole spike (S) protein -a viral membrane glycoprotein which mediates cell uptake 60 by binding to host angiotensin-converting enzyme 2 (ACE2). The antibody response to such 61 vaccines will be polyclonal in nature and will likely include both neutralising and non-62 neutralising antibodies. It is hoped that the neutralising component will be sufficient to 63",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "provide long-term SARS-CoV-2 immunity following vaccination, although other potential 64",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "confounders may exist, such as raising antibodies which mediate antibody-dependent 65 enhancement (ADE) of viral entry 8-10 . While ADE is not proven for SARS-CoV-2, prior studies 66 of SARS-CoV-1 in non-human primates showed that, while some S protein antibodies from 67 human SARS-CoV-1 patients were protective, others enhanced the infection via ADE 11 . An 68 alternative could be to support passive immunity to SARS-CoV-2, by administering one, or a 69 small cocktail of, well-characterised, neutralising antibodies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Patients recovering from COVID-19 have already been screened to identify 71 neutralising antibodies, following analysis of relatively small numbers (100-500) of antibody 72 sequences 12,13 . A more extensive BCR repertoire analysis was performed on six patients in 73",
            "cite_spans": [],
            "ref_spans": [],
            "section": "70"
        },
        {
            "text": "Stanford, USA with signs and symptoms of COVID-19 who also tested positive for SARS-CoV-74 2 RNA 14 . Although no information was provided on the patient outcomes in that study, the 75 analysis demonstrated preferential expression of a subset of immunoglobulin heavy chain 76",
            "cite_spans": [],
            "ref_spans": [],
            "section": "70"
        },
        {
            "text": "(IGH) V gene segments with relatively little somatic hypermutation and showed evidence of 77 convergent antibodies between patients.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "70"
        },
        {
            "text": "To drive a deeper understanding of the nature of humoral immunity to SARS-CoV-2 79 infection and to identify potential therapeutic antibodies to SARS- increase) in the COVID-19 patients ( Figure 1A ). All of these V gene segments have been 113",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 188,
                    "end": 197,
                    "text": "Figure 1A",
                    "ref_id": null
                }
            ],
            "section": "78"
        },
        {
            "text": "previously observed in SARS-CoV-1 or SARS-CoV-2 specific antibodies 16 . IGHV4-34 has been 114",
            "cite_spans": [],
            "ref_spans": [],
            "section": "78"
        },
        {
            "text": "shown to bind both autoantigens 17 and commensal bacteria 18 and has been associated 115",
            "cite_spans": [],
            "ref_spans": [],
            "section": "78"
        },
        {
            "text": "with SLE 19 . Our data extends this, showing that the proportion of sequences containing the 116 autoreactive AVY & NHS sequence motifs within the IGHV region is significantly more 117 frequent in improving COVID-19 patients compared to stable or deteriorating COVID-19 118 patients, specifically in the IGHG1 isotype subclass (p-value = 0.038; Supplementary Figure  119 2). 120",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 359,
                    "end": 370,
                    "text": "Figure  119",
                    "ref_id": null
                }
            ],
            "section": "78"
        },
        {
            "text": "Comparing isotype subclasses showed a significant increase in the relative usage of 121 IGHA1 and IGHG1 in COVID-19 patients ( Figure 1B ) -these are the two first isotype 122",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 127,
                    "end": 136,
                    "text": "Figure 1B",
                    "ref_id": null
                }
            ],
            "section": "78"
        },
        {
            "text": "subclasses that are switched to upon activation of IGHM 20 . There was also an increase in 123 the mean CDRH3 length of the BCRs in the COVID-19 patients, that was most pronounced in 124 the IGHA1, IGHA2 and IGHG1 isotype subclasses ( Figure 1C ). 125 126",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 235,
                    "end": 244,
                    "text": "Figure 1C",
                    "ref_id": null
                }
            ],
            "section": "78"
        },
        {
            "text": "To further investigate the COVID-19-specific B cell response, we analysed the characteristics 128 of the BCR sequences that are consistent with recent B cell activation -somatic 129 hypermutation, and clonal expansion. In healthy controls, for class-switched sequences, 130",
            "cite_spans": [],
            "ref_spans": [],
            "section": "127"
        },
        {
            "text": "there is a clear unimodal distribution of sequences with different numbers of mutations, 131",
            "cite_spans": [],
            "ref_spans": [],
            "section": "127"
        },
        {
            "text": "and a mean mutation count across IGHA and IGHG isotypes of 17.6 ( Figure 2A ). In the 132 COVID-19 samples, the mean mutation count was 14.4, and there was a bimodal 133 distribution with a separate peak of sequences with no mutations. This bimodal distribution 134 was most pronounced in the IGHG1, IGHG3, and IGHA1 isotype subclasses, corresponding to 135 the increased isotype usages. Such a distribution is consistent with an expansion of recently 136",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 66,
                    "end": 75,
                    "text": "Figure 2A",
                    "ref_id": null
                }
            ],
            "section": "127"
        },
        {
            "text": "class-switched B cells that have yet to undergo somatic hypermutation. There was 137 considerable variation between participants in the proportion of unmutated sequences 138",
            "cite_spans": [],
            "ref_spans": [],
            "section": "127"
        },
        {
            "text": "(Supplementary Figure 1) , which had no significant correlation with the number of days 139 since symptom onset (R = 0.09, p = 0.72), but was lower in the deteriorating compared to 140",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 15,
                    "end": 24,
                    "text": "Figure 1)",
                    "ref_id": null
                }
            ],
            "section": "127"
        },
        {
            "text": "improving patients ( Figure 2B ) 141",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 21,
                    "end": 30,
                    "text": "Figure 2B",
                    "ref_id": null
                }
            ],
            "section": "127"
        },
        {
            "text": "To investigate differential clonal expansion between patients, the Shannon diversity 142",
            "cite_spans": [],
            "ref_spans": [],
            "section": "127"
        },
        {
            "text": "index of each repertoire was calculated (while accounting for differences in read depth 143 through subsampling). A more diverse repertoire is indicative of a greater abundance of 144 different clonal expansions. The BCR repertoires of the COVID-19 patients were significantly 145 more diverse than the BCR repertoires of the healthy controls ( Figure 2C ); this increase in 146 diversity was positively correlated with an increased proportion of unmutated sequences (R 147 = 0.44, p = 0.061; Figure 2D ). Interestingly, when we investigated the largest clonal 148",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 345,
                    "end": 354,
                    "text": "Figure 2C",
                    "ref_id": null
                },
                {
                    "start": 493,
                    "end": 502,
                    "text": "Figure 2D",
                    "ref_id": null
                }
            ],
            "section": "127"
        },
        {
            "text": "expansions, despite having a more diverse repertoire, the largest clonal expansions in the 149 COVID-19 samples were larger than in the healthy controls ( Figure 2E ). These large clonal 150 expansions were also highly mutated and had similar levels of mutation between the 151 COVID-19 samples and the healthy controls ( Figure 2F ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 155,
                    "end": 164,
                    "text": "Figure 2E",
                    "ref_id": null
                },
                {
                    "start": 322,
                    "end": 331,
                    "text": "Figure 2F",
                    "ref_id": null
                }
            ],
            "section": "127"
        },
        {
            "text": "Sequence convergence can be used to identify putative SARS-CoV-2 specific 154 antibodies 155",
            "cite_spans": [],
            "ref_spans": [],
            "section": "153"
        },
        {
            "text": "Given the skewing of the B cell response in the COVID-19 patients to specific IGHV genes, 156",
            "cite_spans": [],
            "ref_spans": [],
            "section": "153"
        },
        {
            "text": "we next investigated whether the same similarity was also seen on the BCR sequence level 157 between different participants. Such convergent BCR signatures have been observed in 158 response to other infectious diseases 21 , and may be used to identify disease-specific 159 antibody sequences.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "153"
        },
        {
            "text": "Of the 435,420 total clonotypes across all the COVID-19 patients, 9,646 (2.2%) were 161",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "shared between at least two of the participants ( Figure 3A ). As convergence could occur by 162 chance or be due to an unrelated memory response from commonly encountered 163 pathogens, the healthy control dataset was used to subtract irrelevant BCR sequences. Of 164 the 9,646 convergent clonotypes, 1,442 (14.9%) were also present in at least one of the 40 165 healthy control samples. As expected, of the convergent clonotypes that were also present 166",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 50,
                    "end": 59,
                    "text": "Figure 3A",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "in the healthy control samples, the mean mutation count was significantly greater ( Figure  167 3B), and the mean CDRH3 length significantly shorter ( Figure 3C ) than the convergent 168 clonotypes that were unique to the COVID-19 patients. 169",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 84,
                    "end": 95,
                    "text": "Figure  167",
                    "ref_id": null
                },
                {
                    "start": 151,
                    "end": 160,
                    "text": "Figure 3C",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "To identify a set of SARS-CoV-2-specific antibody sequences with high confidence, 170",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "we identified 777 convergent clonotypes that were shared between at least four of the 171 COVID-19 patients, but not seen in the healthy controls. In parallel, for a comparison of 172 convergent signatures, we performed the same analysis on a cohort of seven metastatic 173 breast cancer patient biopsy samples 22 , which identified 469 convergent clonotypes. These 174 convergent clonotypes were highly specific to each disease cohort ( Figure 3D ). The 777 175",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 438,
                    "end": 447,
                    "text": "Figure 3D",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "COVID-19 convergent clonotypes had low mutation levels, with a mean mutation count of 2, 176",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "and only 51 clonotypes with a mean mutation greater than 5. The sequences within the 177 convergent clonotypes were primarily of the IGHG1 (70%) and IGHA1 (16%) subclasses 178",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "(Supplementary Figure 3A) . The convergent clonotypes used a diversity of IGHV gene 179 segments, with IGHV3-30, IGHV3-30-3 and IGHV3-33 as the most highly represented 180",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 15,
                    "end": 25,
                    "text": "Figure 3A)",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "(Supplementary Figure 3B ). This IGHV gene usage distribution differs between that of the 181 total repertoire, and IGHV3-30 is also the most highly used IGHV gene in the CoV-AbDab 16 . 182",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 15,
                    "end": 24,
                    "text": "Figure 3B",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "We next tested whether these convergent clonotypes correlated with disease 183 severity. Indeed, 25 of these convergent clonotypes were found to associate with clinical 184 symptoms after correcting for multiple testing, of which 22 were observed at a significantly 185",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "higher frequency in improving patients ( Figure 3E and Supplementary Figure 4 ). This is a 186 significantly higher proportion associated with clinical symptoms compared to that expected 187 by chance (p-value = 0.018 by random permutations of labels). Interestingly, some of these 188",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 41,
                    "end": 50,
                    "text": "Figure 3E",
                    "ref_id": null
                },
                {
                    "start": 69,
                    "end": 77,
                    "text": "Figure 4",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "clonotypes are common in patients comprising >0.1 % of a patient's repertoire. 189",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "Furthermore, the convergent clonotypes that are associated with clinical symptoms cluster 190 together ( Figure 3F ) and are found primarily in the IGHA1 and IGHG1 isotypes ( Figure 3G ). To further explore whether the convergent clonotypes observed in our study were indeed 195 disease specific, and to determine whether such convergence was common across studies 196",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 105,
                    "end": 114,
                    "text": "Figure 3F",
                    "ref_id": null
                },
                {
                    "start": 175,
                    "end": 184,
                    "text": "Figure 3G",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "and geographic regions, we compared these 777 convergent clonotypes to public B cell 197",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "datasets. 198",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "First, we compared our data to RNAseq data of bronchoalveolar lavage fluid 199 obtained from five of the first infected patients in Wuhan, China 23 . These samples were 200",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "obtained for the purpose of metagenomic analyses to identify the aetiological agent of the 201 novel coronavirus but were re-analysed to determine whether we could extract any 202 transcripts from BCRs. From the 10,038,758 total reads, we were able to identify 16 unique 203",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "CDR3 AA sequences ( 204 Supplementary Table 2) . Of these, one had an exact AA match to a sequence in our 205 data and shared the same V gene segment (IGHV3-15), and J gene segment (IGHJ4) usage 206",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 24,
                    "end": 46,
                    "text": "Supplementary Table 2)",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "( Figure 4A) . The sequence had a CDRH3 AA length of 12, so such a match is unlikely to occur 207 due to chance alone. The clonotype that the sequence belonged to contained 699 total 208 sequences and was convergent between 8 of our 19 COVID-19 patients, but not present in 209 the healthy controls. The clonotype was highly diverse, and the sequences had evidence of 210 low mutation from germline, with a mean mutation count over all sequences of 4.8 211",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 2,
                    "end": 12,
                    "text": "Figure 4A)",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "(Supplementary Figure 5) . 212",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 15,
                    "end": 24,
                    "text": "Figure 5)",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "Next, we compared our 777 convergent clonotypes to CoV-AbDab -the Coronavirus 213",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "Antibody Database [accessed 10 th May 2020] 16 . At the time of access, this database 214 contained 80 non-redundant CDRH3 sequences from published and patented antibodies 215 proven to bind SARS-CoV-1 and/or SARS-CoV-2. We found 6 of our clonotypes to have high 216 CDRH3 homology to the antibodies in CoV-AbDab ( Figure 4B and Supplementary Figure 6 ). 217",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 315,
                    "end": 324,
                    "text": "Figure 4B",
                    "ref_id": null
                },
                {
                    "start": 343,
                    "end": 351,
                    "text": "Figure 6",
                    "ref_id": null
                }
            ],
            "section": "160"
        },
        {
            "text": "The most striking similarity was to S304, a previously described SARS-CoV-1 and SARS-CoV-2 218 receptor-binding domain antibody able to contribute to viral neutralisation 24 . One of the 219 777 convergent clonotypes contained sequences with an exact CDRH3 AA sequence match 220 and utilised the same IGHV and IGHJ germline gene segments to S304. This clonotype was 221 convergent across 6 patients and had a mean mutation count of 1. We there was also evidence of a proportion of the response arising from memory recall. In the 254 COVID-19 patients, the largest clonal expansions were highly mutated, equivalent to the 255 level observed in healthy control cohort. Such a secondary response to SARS-CoV-2 has 256 been previously observed 26 , and may be due to recall of B cells activated in response to 257",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "previously circulating human coronaviruses, as recently highlighted 27,28 . 258",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "We observed a potential relationship between repertoire characteristics and disease 259 state, with improving patients showing a tendency towards a higher proportion of 260 unmutated sequences. The increased prevalence of autoreactive IGHV4-34 sequences in 261",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "improving COVID-19 patients compared to stable or deteriorating COVID-19 patients 262",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "potentially suggests a role for natural or autoreactive antibodies in resolving infection and 263",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "lower risk of pathology. There is a clear need to expand on these findings by using larger 264 sample cohorts and gathering more clinical data to aid understanding of the differences 265 between individuals that respond with mild versus severe disease and have different 266 recovery patterns. Building upon these observations could help to inform the future 267 development of diagnostic assays to monitor and predict the progression of disease in 268 infected patients.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "A large number (777) of highly convergent clonotypes unique to COVID-19 were 270",
            "cite_spans": [],
            "ref_spans": [],
            "section": "269"
        },
        {
            "text": "identified. Our approach of subtracting the convergent clonotypes also observed in healthy 271 controls 15 , allowed us to identify convergence specific to the disease cohort. The unbiased 272 nature of the BCR repertoire analysis approach means that, whilst these convergent 273",
            "cite_spans": [],
            "ref_spans": [],
            "section": "269"
        },
        {
            "text": "clonotypes are likely to include many antibodies to the spike protein and other parts of the 274 virus they may also include other protective antibodies, including those to host proteins.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "269"
        },
        {
            "text": "Characterisation of the heavy chains we have identified, coupled with matched light chains 276 to generate functional antibodies will permit analysis of the binding sites and neutralising 277 potential of these antibodies. The report that plasma derived from recently recovered 278 donors with high neutralising antibody titres can improve the outcome of patients with 279",
            "cite_spans": [],
            "ref_spans": [],
            "section": "275"
        },
        {
            "text": "severe disease 29 , supports the hypotheses that intervention with a therapeutic antibody 280 has the potential to be an effective treatment. A manufactured monoclonal antibody or 281 combination of antibodies would also provide a simpler, scalable and safer approach than 282 plasma therapy. 283",
            "cite_spans": [],
            "ref_spans": [],
            "section": "275"
        },
        {
            "text": "Sequence convergence between our 777 convergent clonotypes with heavy chains 284 from published and patented SARS-CoV-1 and SARS-CoV-2 antibodies 16 supports several 285",
            "cite_spans": [],
            "ref_spans": [],
            "section": "275"
        },
        {
            "text": "observations. Firstly, it demonstrates that our approach of finding a convergent sequence 286 signature is a useful method for enriching disease-specific antibodies, as we find matches to 287",
            "cite_spans": [],
            "ref_spans": [],
            "section": "275"
        },
        {
            "text": "known SARS-CoV spike-binding antibodies. Secondly, it shows that the clonotypes observed 288",
            "cite_spans": [],
            "ref_spans": [],
            "section": "275"
        },
        {
            "text": "in response to SARS-CoV-2 overlap with those to SARS- showing that convergence can be seen both between different locations, and different 302 sample types. We believe that the identification of such high BCR sequence convergence 303 between geographically distinct and independent datasets could be highly significant and 304",
            "cite_spans": [],
            "ref_spans": [],
            "section": "275"
        },
        {
            "text": "validates the disease association of the clonotypes, as well as the overall approach. 305",
            "cite_spans": [],
            "ref_spans": [],
            "section": "275"
        },
        {
            "text": "In summary, our BCR repertoire analysis provides information on the specific nature 306 of the B cell response to SARS-CoV-2 infection. The information generated has the potential 307",
            "cite_spans": [],
            "ref_spans": [],
            "section": "275"
        },
        {
            "text": "to facilitate the treatment of COVID-19 by supporting diagnostic approaches to predict the 308 progression of disease, informing vaccine development and enabling the development of 309 therapeutic antibody treatments and prophylactics. 310",
            "cite_spans": [],
            "ref_spans": [],
            "section": "275"
        },
        {
            "text": "Clinical information gathering were collected by members of the direct care team, including duration of symptoms prior to 318 blood sample collection. Current severity was mapped to the WHO Ordinal Scale of Severity. 319",
            "cite_spans": [],
            "ref_spans": [],
            "section": "312"
        },
        {
            "text": "Whether patients at time of sample collection were clinically Improving, Stable or 320",
            "cite_spans": [],
            "ref_spans": [],
            "section": "312"
        },
        {
            "text": "Deteriorating was subjectively determined by the direct clinical team prior to any sample 321",
            "cite_spans": [],
            "ref_spans": [],
            "section": "312"
        },
        {
            "text": "analysis. This determination was primarily made on the basis of whether requirement for 322 supplemental oxygen was increasing, stable, or decreasing comparing current day to 323 previous three days.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "312"
        },
        {
            "text": "Sample collection and initial processing",
            "cite_spans": [],
            "ref_spans": [],
            "section": "325"
        },
        {
            "text": "Blood samples were centrifuged at 150 xg for 15 minutes at room temperature to separate 327 plasma. The cell pellet was resuspended with phosphate-buffered saline (PBS without 328 calcium and magnesium, Sigma) to 20 ml, layered onto 15 ml Ficoll-Paque Plus (GE 329",
            "cite_spans": [],
            "ref_spans": [],
            "section": "326"
        },
        {
            "text": "Healthcare) and then centrifuged at 400 xg for 30 minutes at room temperature without 330 brake. Mononuclear cells (PBMCs) were extracted from the buffy coat and washed twice 331",
            "cite_spans": [],
            "ref_spans": [],
            "section": "326"
        },
        {
            "text": "with PBS at 300 xg for 8 min. PBMCs were counted with Trypan blue (Sigma) and viability of 332 >96% was observed. 5x10 6 PBMCs were resuspended in RLT (Qiagen) and incubated at room 333 temperature for 10 min prior to storage at -80\u00b0C. Consecutive donor samples with sufficient 334",
            "cite_spans": [],
            "ref_spans": [],
            "section": "326"
        },
        {
            "text": "RLT samples progressed to RNA preparation and BCR preparation and are included in this 335 manuscript. 336",
            "cite_spans": [],
            "ref_spans": [],
            "section": "326"
        },
        {
            "text": "Metastatic breast cancer biopsy samples were collected and RNA extracted as part 337",
            "cite_spans": [],
            "ref_spans": [],
            "section": "326"
        },
        {
            "text": "of a previously reported cohort 22 . 338 339",
            "cite_spans": [],
            "ref_spans": [],
            "section": "326"
        },
        {
            "text": "Total RNA from 5x10 6 PBMCs was isolated using RNeasy kits (Qiagen). First-strand cDNA was 341 generated from total RNA using SuperScript RT IV (Invitrogen) and IgA and IgG isotype 342 specific primers 30 including UMIs at 50 o C for 45 min (inactivation at 80 o C for 10 min). 343",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "The resulting cDNA was used as template for High Fidelity PCR amplification (KAPA, 344",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "Roche) using a set of 6 FR1-specific forward primers 30 including sample-specific barcode 345 sequences (6bp) and a reverse primer specific to the RT primer (initial denaturation at The Immcantation framework (docker container v3.0.0) was used for sequence processing 357 31,32 . Briefly, paired-end reads were joined based on a minimum overlap of 20 nt, and a max 358 error of 0.2, and reads with a mean phred score below 20 were removed. Primer regions, 359",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "including UMIs and sample barcodes, were then identified within each read, and trimmed. 360",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "Together, the sample barcode, UMI, and constant region primer were used to assign 361 molecular groupings for each read. Within each grouping, usearch 33 , was used to subdivide 362 the grouping, with a cutoff of 80% nucleotide identity, to account for randomly overlapping 363",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "UMIs. Each of the resulting groupings is assumed to represent reads arising from a single 364",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "RNA. Reads within each grouping were then aligned, and a consensus sequence determined. 365",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "For each processed sequence, IgBlast 34 was used to determine V, D and J gene 366 segments, and locations of the CDRs and FWRs. Isotype was determined based on 367 comparison to germline constant region sequences. Sequences annotated as unproductive 368",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "by IgBlast were removed. The number of mutations within each sequence was determined 369",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "using the shazam R package 32 . 370",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "Sequences were clustered to identify those arising from clonally related B cells; a 371 process termed clonotyping. Sequences from all samples were clustered together to also 372 identify convergent clusters between samples. Clustering was performed using a previously 373 described algorithm 35 . Clustering required identical V and J gene segment usage, identical 374 CDRH3 length, and allowed 1 AA mismatch for every 10 AAs within the CDRH3. Cluster 375 centers were defined as the most common sequence within the cluster. Lineages were 376 reconstructed from clusters using the alakazam R package 36 . The similarity tree of the 377 convergent clonontype CDR3 sequences was generated through a kmer similarity matrix 378 between sequences in R.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "340"
        },
        {
            "text": "Public healthy control data processing",
            "cite_spans": [],
            "ref_spans": [],
            "section": "380"
        },
        {
            "text": "The healthy control BCR sequence dataset used here has been described previously 15 . Only 382 samples from participants aged 10 years or older, and from peripheral blood were used, 383",
            "cite_spans": [],
            "ref_spans": [],
            "section": "381"
        },
        {
            "text": "resulting in a mean age of 28 (range: 11-51). Furthermore, only class-switched sequences 384",
            "cite_spans": [],
            "ref_spans": [],
            "section": "381"
        },
        {
            "text": "were considered.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "381"
        },
        {
            "text": "Public SARS-CoV-2 bronchoalveolar lavage RNAseq data processing",
            "cite_spans": [],
            "ref_spans": [],
            "section": "386"
        },
        {
            "text": "The bronchoalveolar lavage data comes from a previously published study of SARS-CoV-2 388 infection 23 , with data available under the PRJNA605983 BioProject on NCBI. MIXCR v3.0.3 389 was used, with default settings, to extract reads mapping to antibody genes from the total 390",
            "cite_spans": [],
            "ref_spans": [],
            "section": "387"
        },
        {
            "text": "RNASeq data 37 .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "387"
        },
        {
            "text": "Public CoV-AbDab data processing",
            "cite_spans": [],
            "ref_spans": [],
            "section": "392"
        },
        {
            "text": "All public CDRH3 AA sequences associated with published or patented SARS-CoV-1 or SARS-394",
            "cite_spans": [],
            "ref_spans": [],
            "section": "393"
        },
        {
            "text": "CoV-2 binding antibodies were mined from CoV-AbDab 16 , downloaded on 10 th May 2020. A 395 total of 80 non-redundant CDRH3s were identified (100% identity threshold). These 396 sequences were then clustered alongside the representative CDRH3 sequence from each of 397 our 777 convergent clones using CD-HIT 38 , at an 80% sequence identity threshold (allowing 398 at most a CDRH3 length mismatch of 1 AA). Cluster centres containing at least one CoV-399",
            "cite_spans": [],
            "ref_spans": [],
            "section": "393"
        },
        {
            "text": "AbDab CDRH3 and one convergent clone CDRH3 were further investigated.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "393"
        },
        {
            "text": "Public COVID-19 BCR sequence data processing",
            "cite_spans": [],
            "ref_spans": [],
            "section": "401"
        },
        {
            "text": "The fourteen MiSeq \"read 1\" FASTQ datasets from the six SARS-CoV-2 patients analysed in 403",
            "cite_spans": [],
            "ref_spans": [],
            "section": "402"
        },
        {
            "text": "Nielsen ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "402"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Outbreak of pneumonia of unknown etiology in 427",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "W"
                    ],
                    "last": "Stratton",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "W"
                    ],
                    "last": "Tang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "The mystery and the miracle",
            "authors": [
                {
                    "first": "China",
                    "middle": [],
                    "last": "Wuhan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Journal of Medical Virology",
            "volume": "92",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Clinical features of patients infected with 2019 novel coronavirus in 430 Wuhan",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "China. Lancet",
            "volume": "395",
            "issn": "",
            "pages": "497--506",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Receptor Recognition by the Novel 432 Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of 433 SARS Coronavirus",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Graham",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Baric",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J. Virol",
            "volume": "94",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Epidemiological and clinical characteristics of 99 cases of 2019 novel 435 coronavirus pneumonia in Wuhan, China: a descriptive study",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "507--513",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "A randomized, controlled trial of Ebola virus disease therapeutics",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mulangu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Comparison of a Novel Human Rabies Monoclonal Antibody to 440 Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "J"
                    ],
                    "last": "Gogtay",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Development of a Humanized Monoclonal Antibody (MEDI-493) 444 with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Johnson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "J. Infect",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Antibody-dependent SARS coronavirus infection is mediated by 447 antibodies against spike proteins",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "F"
                    ],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Biochem. Biophys. Res. Commun",
            "volume": "451",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Tetro",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "22",
            "issn": "",
            "pages": "72--73",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Immunodominant SARS coronavirus epitopes in humans elicited both 454 enhancing and neutralizing effects on infection in non-human primates",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sharma",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Microbes and Infection",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.micinf.2020.03.005.45311"
                ]
            }
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Identification of neutralizing human monoclonal antibodies from 459 Italian Covid-19 convalescent patients",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Brouwer",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "bioRxiv",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.05.12.088716.45813"
                ]
            }
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Maturation of na\u00efve and antigen-experienced B-cell receptor 464 repertoires with age",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ghraichy",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "bioRxiv",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.21203/rs.3.rs-27220/v1.46315"
                ]
            }
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Nucleotide sequence analysis of the V regions of two IgM cold 468 agglutinins: Evidence that the V(H)4-21 gene segment is responsible for the major 469 cross-reactive idiotype",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Pascual",
                    "suffix": ""
                }
            ],
            "year": 1991,
            "venue": "Coronavirus Antibody Database. bioRxiv",
            "volume": "146",
            "issn": "",
            "pages": "4385--4391",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.05.15.077313.46717"
                ]
            }
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Self-reactive VH4-34-expressing IgG B cells recognizecommensal 471 bacteria",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "N"
                    ],
                    "last": "Schickel",
                    "suffix": ""
                }
            ],
            "year": 1991,
            "venue": "J. Exp. Med",
            "volume": "214",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Diversity, cellular origin and autoreactivity of antibody-secreting 473 cell population expansions in acute systemic lupus erythematosus",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Tipton",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Nat. Immunol",
            "volume": "16",
            "issn": "",
            "pages": "755--765",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Lineage tracing of human B cells reveals the in vivo landscape of 476 human antibody class switching",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Horns",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Elife",
            "volume": "5",
            "issn": "",
            "pages": "1--20",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Convergent Antibody Signatures in Human Dengue",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Parameswaran",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Cell Host 478 Microbe",
            "volume": "13",
            "issn": "",
            "pages": "691--700",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "The Genomic and Immune Landscapes of Lethal 480 Metastatic Breast Cancer. Cell Rep",
            "authors": [
                {
                    "first": "De",
                    "middle": [],
                    "last": "Mattos-Arruda",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "27",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "A pneumonia outbreak associated with a new coronavirus of probable 482 bat origin",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "579",
            "issn": "",
            "pages": "270--273",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "26. Wec, A. Z. et al. Broad sarbecovirus neutralizing antibodies define a key site of 488 vulnerability on the SARS-CoV-2 spike protein",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Pinto",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "bioRxiv",
            "volume": "485",
            "issn": "25",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.04.07.023903"
                ]
            }
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Targets of T cell responses to SARS-CoV-2 coronavirus in humans with 491 COVID-19 disease and unexposed individuals",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Grifoni",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.cell.2020.05.015"
                ]
            }
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Ng",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Effectiveness of convalescent plasma therapy in severe COVID-19 496 patients",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Biorxiv ; Duan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Proc. Natl. Acad. Sci",
            "volume": "29",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.05.14.095414.495"
                ]
            }
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Design and standardization of PCR primers and protocols 498 for detection of clonal immunoglobulin and T-cell receptor gene recombinations in 499 suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-500 3936",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "J M"
                    ],
                    "last": "Van Dongen",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Leukemia",
            "volume": "17",
            "issn": "",
            "pages": "2257--317",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "pRESTO: a toolkit for processing high-throughput 502 sequencing raw reads of lymphocyte receptor repertoires",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Vander Heiden",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Bioinformatics",
            "volume": "30",
            "issn": "",
            "pages": "1930--1932",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Change-O: A toolkit for analyzing large-scale B cell immunoglobulin 505 repertoire sequencing data",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "T"
                    ],
                    "last": "Gupta",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Bioinformatics",
            "volume": "31",
            "issn": "",
            "pages": "3356--3358",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Search and clustering orders of magnitude faster than BLAST",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "C"
                    ],
                    "last": "Edgar",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Supplementary Figure 1. Distribution of sequences with different numbers of mutations from germline",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF2": {
            "text": "sequence convergence signatures are shared between different 193 COVID-19 studies in different locations and from different anatomical sites 194",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "have used deep sequencing of the BCR heavy chain repertoire to evaluate the B cell 239 responses of 19 individuals with COVID-19. In agreement with previous studies, there was a 240 skewing of the repertoire in the response to SARS-CoV-2 infection, with an increased use of 241 certain V genes, an increase in the proportion of antibodies with longer CDRH3s, and an 242 altered isotype subclass distribution 14 . The significantly increased usage of IGHA1 observed 243 in the COVID-19 patients is in line with mucosal responses, where the longer hinge in IGHA1 244 compared to IGHA2 may offer advantages in antigen recognition by allowing higher avidity 245 bivalent interactions with distantly spaced antigens 25 . 246 As anticipated, given the novel nature of the virus, that SARS-CoV-2 infection largely 247 stimulated a characteristically na\u00efve response, rather than a reactivation of pre-existing 248 memory B cells -(1) there was an increased prevalence of unmutated antigen-experienced 249 class-switched BCR sequences, (2) an increase in the diversity of class-switched IGHA and 250 IGHG BCRs, and (3) an increase in the usage of isotype subclasses that are associated with 251 recent viral immunity. These observations are consistent with an increase in the frequency 252 of recently activated B cells in response to SARS-CoV-2. In addition to the na\u00efve response, 253",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "95 o C 346 for 3 min, 25 cycles at 98 o C for 20 sec, 60 o C for 30 sec, 72 o C for 1 min and final extension 347 at 72 o C for 7 min). The amount of Ig amplicons (~450bp) was quantified by TapeStation 348 (Beckman Coulter) and gel-purified. 349 Dual-indexed sequencing adapters (KAPA) were ligated onto 500ng amplicons per 350 patient using the HyperPrep library construction kit (KAPA) and the adapter-ligated libraries 351 were finally PCR-amplified for 3 cycles (98 o C for 15 sec, 60 o C for 30 sec, 72 o C for 30 sec, 352 final extension at 72 o C for 1min). Pools of 10 and 9 libraries were sequenced on an Illumina 353MiSeq using 2x300 bp chemistry.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "B cell responses to SARS-COV-2 infection. A) IGHV gene segment usage distribution per isotype subclass. B) Isotype 565 subclass distribution between IGHA and IGHG subclasses, and C) mean BCR CDRH3 lengths from COVID-19 patients 566 compared to healthy controls. For A-C, bars show mean values +/-standard error of the mean. Comparisons performed 567 using t-tests, with adjusted p values using Bonferroni correction for multiple comparisons; * p < 0.05, ** p < 0.005, *** Response characteristics of SARS-CoV-2 infection. A) Distribution of sequences with different numbers of 571 mutations from germline. B) Relationship between the proportion of the repertoire comprised by unmutated sequences, 572 and the disease state C) Individual sequences were clustered together into related groups to identify clonal expansions 573 (clonotypes). Diversity of all clonotypes in the repertoire calculated using the Shannon diversity index. To normalise for 574 different sequence numbers for each sample, a random subsample of 1,000 sequences was taken. D) Correlation between 575 the Shannon diversity index, and the proportion of unmutated sequences. E) The percent of all sequences that fall into the 576 largest 10 clonotypes. F) Mean number of mutations of all sequences in the largest 10 clonotypes.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Convergent BCR sequence signature within individuals infected with SARS-CoV-2. A) Data from all patients and 580 healthy controls were clustered together to identify convergent clonotypes. Shown is the number of clonotypes shared by 581 different numbers of participants, grouped by whether the clonotypes are also present in the healthy control dataset. Of the 582 convergent clonotypes, B) the mean mutation count, and C) the CDRH3 AA sequence length was compared between those 583 that were convergent only within the SARS-CoV-2 patients, and those that were also convergent with the healthy control 584 dataset. D) Heatmap of the 777 convergent COVID-19-associated clonotypes (observed between 4 or more COVID-19 585 participants) with the 469 convergent clonotypes from seven metastatic breast cancer (BC) patient biopsy samples, 586 demonstrating that the convergent signatures are unique to each disease cohort. E) Percentage frequencies of four example 587 convergent clonotypes grouped by clinical status. F) Similarity tree of convergent clonotype cluster centers that are 588 significantly associated with clinical status. Groups (i) and (ii) indicate groups of similar convergent clonotypes. An 589 alignment of group (ii) provided adjacent. G) Proportions of IGHA and IGHG of the convergent clonotypes that are 590 associated with patients with improving symptoms. 591 Matches of the 777 convergent clonotypes identified in the present study to other SARS-CoV-2 studies. A) CDRH3 593 sequence, and IGHV/IGHJ gene segments of a sequence identified in the bronchoalveolar lavage fluid of a SARS-CoV-2 594 patient from a Chinese cohort (shown across the top in black text), and a CDRH3 AA sequence logo unpacking the sequence 595 diversity present in the convergent clonotype found in the COVID-19 patients in this study that had an exact AA match. B) 596 CDRH3 sequence, and IGHV/IGHJ gene segment of an antibody in the CoV-AbDab (S304) that has SARS-CoV-1 and SARS-597 CoV-2 neutralising activity, alongside a CDRH3 AA sequence logo unpacking the sequence diversity in the convergent 598 clonotype found in the COVID-19 patients in this study that had an exact AA match. C) Comparison of convergent 599 clonotypes to the BCR data from Nielsen et al 14 . Plotted along the x-axis are the 405 convergent clonotypes represented in 600 at least one Nielsen et al. dataset. Each row represents a separate BCR repertoire from Nielsen et al.; pink shading indicates 601 that the convergent clonotype has a match in the Nielsen dataset.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "COVID-19 disease samplesBlood samples were collected from n=19 patients admitted to hospital with acute COVID-19",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "number of clonotype matches to 204. There was one of the 777 convergent clonotypes that 232was found across all six of the Stanford patients, and 17 clonotypes that were found in at",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "and the USA 14 . The dataset from the USA is also from BCR sequencing of the peripheral 297 blood of COVID-19 patients, and here we found matches to 405 of our 777 clonotypes. The 298dataset from China was from total RNA sequencing of the bronchoalveolar lavage fluid of 299 SARS-CoV-2 infected patients. Only 16 unique CDRH3 sequences could be identified in this 300whole dataset, but one of them matched a convergent clonotype in the current study, 301",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "et al. 14 were downloaded from the Sequence Read Archive 39 . IgBlast 34 was used to 404 identify heavy chain V, D, and J gene rearrangements and antibody regions. Unproductive 405 sequences, sequences with out-of-frame V and J genes, and sequences missing the CDRH3 406 region were removed from the downstream analysis. Sequences with 100% amino acid and 407 isotype matches were collapsed. To circumvent the disparity in collapsed dataset sizes 408 between pairs of replicates, we selected the replicate with the highest number of sequences Convergent Clonotyping Matching to Public Repertoires 412 The public SARS-CoV-2-positive 14 and healthy control BCR repertoires 40 were scanned for 413 clonotype matches to our 777 convergent clonotype cluster centres. A BCR repertoire sequence was determined as a match if it had identical V and J genes, the same length 415 CDRH3, and was within 1 AA mismatch per 10 CDRH3 AAs to a convergent clonotype Statistical analysis and graphing 419 Statistical analysis and plotting were performed using R 41 . Plotting was performed using 420 ggplot2 42 . Sequence logos were created using ggseqlogo 43 . Specific statistical tests used are 421 detailed in the figure legends. Correlations of IGHV4-34 autoreactive motifs and convergent 422 clonotypes was performed by manova in R. 423 424",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "COVID-19 BCR sequence data will be made available upon publication. IGHV2-26  IGHJ3  CARDSGRHLGPFDIW  IGHV1-2  IGHJ3  CATPYYYDGGLDAFDIW  IGHV3-74  IGHJ5  CARDLSRTNWFDPW  IGHV3-15  IGHJ4  CTTDLHDYGDSDYW  IGHV3-15  IGHJ4  CTTDFGGMITFGGVLRRI  IGHV3-21  IGHJ4  CARAQSRGGYDSFFDFW  IGHV3-21  IGHJ4  CGRGGPGTGIDYW  IGHV4-59  IGHJ5 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 68,
                    "end": 323,
                    "text": "IGHV2-26  IGHJ3  CARDSGRHLGPFDIW  IGHV1-2  IGHJ3  CATPYYYDGGLDAFDIW  IGHV3-74  IGHJ5  CARDLSRTNWFDPW  IGHV3-15  IGHJ4  CTTDLHDYGDSDYW  IGHV3-15  IGHJ4  CTTDFGGMITFGGVLRRI  IGHV3-21  IGHJ4  CARAQSRGGYDSFFDFW  IGHV3-21  IGHJ4  CGRGGPGTGIDYW  IGHV4-59  IGHJ5",
                    "ref_id": null
                }
            ],
            "section": "annex"
        }
    ]
}